ARMATA PHARMACEUTICALS, INC. Cash and Restricted Cash
ARMATA PHARMACEUTICALS, INC. (ARMP) had Cash and Restricted Cash of $28.07 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-12
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $28.07M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $8.87M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $14.08M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $20.15M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $28.07M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $8.87M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $14.08M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $20.15M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $9.72M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $17.08M 10-Q · filed 2026-05-13 |
| 2024-12-31 | $14.77M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $22.62M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $31.89M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $43.34M 10-Q · filed 2025-05-14 |
| 2023-12-31 | $19.24M 10-K · filed 2026-03-25 |
| 2023-09-30 | $29.78M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $18.18M 10-Q · filed 2024-08-13 |
| 2023-03-31 | $30.83M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $20.81M 10-K · filed 2025-03-21 |
| 2022-09-30 | $31.34M 10-Q · filed 2023-11-14 |
| 2022-06-30 | $42.94M 10-Q · filed 2023-08-14 |
| 2022-03-31 | $52.37M 10-Q · filed 2023-05-11 |
| 2021-12-31 | $11.49M 10-K · filed 2024-03-21 |
| 2021-09-30 | $13.28M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $18.74M 10-Q · filed 2022-08-11 |
| 2021-03-31 | $23.66M 10-Q · filed 2022-05-12 |
| 2020-12-31 | $10.85M 10-K · filed 2023-03-16 |
| 2020-09-30 | $17.09M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $20.99M 10-Q · filed 2021-08-12 |
| 2020-03-31 | $24.81M 10-Q · filed 2021-05-13 |
| 2019-12-31 | $6.73M 10-K · filed 2022-03-17 |
| 2019-09-30 | $9.39M 10-Q · filed 2020-11-12 |
| 2019-06-30 | $13.89M 10-Q · filed 2020-08-13 |
| 2019-03-31 | $6.86M 10-Q · filed 2020-05-14 |
| 2018-12-31 | $10.46M 10-K · filed 2021-03-18 |
| 2018-09-30 | $14.19M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $16.22M 10-Q · filed 2019-08-14 |
| 2017-12-31 | $12.28M 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |